MedPath

Biologic MateR clinical performance test for ADA and TCZ Efficacy predictio

Not Applicable
Conditions
rheumatoid arthritis
Registration Number
JPRN-UMIN000015616
Lead Sponsor
Biologic Mate Study Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Be against the guideline of ADA,TCZ and MTX Patient is otherwise ineligible to participate in this study in the investigator's opinion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ADAMTS5mRNA dose at 0wk. Remission rate and ACR response at 24wk.
Secondary Outcome Measures
NameTimeMethod
SDAI CDAI and Boolean rates at 24wk.
© Copyright 2025. All Rights Reserved by MedPath